Portopulmonary hypertension (PoPH) is a pulmonary vascular complication of chronic liver disease. The condition is defined as precapillary pulmonary arterial hypertension (PAH) in the context of portal hypertension. Characterized by vasoconstriction and vascular remodeling of pulmonary arterial vessels, PoPH results in increased pulmonary vascular resistance and right ventricular failure. If left untreated, PoPH has poor prognosis indicated by a 5‐year survival of 4%–14%. The mainstay of treatment consists of vasomodulator therapy, although additional clinical trials in this specific patient population are needed. Liver transplantation should be considered only in carefully selected patients. This review summarizes current knowledge on PoPH pathogenesis and provides an update on screening, diagnosis and management.
Portopulmonary hypertension (PoPH) is a complex and underrecognized form of pulmonary arterial hypertension arising in the setting of portal hypertension, in which outcomes are driven by the interplay between pulmonary vascular disease and liver dysfunction. Despite advances in hemodynamic definitions and targeted ther...
J. Donate, S. del Prado, Andrés Tenes et al.· Annals of Hepatology· 0 citations
Combining SaO2 with RHC-derived parameters provides a more comprehensive and individualized assessment of disease severity in VSD-PAH than hemodynamics alone and may provide a hypothesis-generating framework for cardiovascular specialists.
Wei-Jie Tang, Jin-Zhou Cai, Shi-Biao Zhang et al.· Clinical and experimental hy...· 0 citations
It is suggested that short‐term perioperative sotatercept can serve as an effective acute rescue therapy to safeguard high‐risk surgical interventions in critical pediatric PAH.
This review offers a contemporary analysis of the evolving landscape of pulmonary hypertension (PH) diagnosis and management. It synthesizes current evidence on disease mechanisms and therapeutic approaches, with particular emphasis on the pivotal changes introduced by the 2022 ESC/ERS guidelines. Central to this updat...
O. Г. Shust, D. M. Pisaryk, N. С. Anisova et al.· Military Medicine· 0 citations
Pediatric pulmonary arterial hypertension carries a poor prognosis. Reversed Potts shunt has been proposed as a bridge from medical therapy to lung transplantation, yet evidence supporting its ability to preserve right ventricular function and improve symptoms in this population remains limited.
Pediatric...
X. Lin, J. Yuan, M. Zeng et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.